$22M
Million in NET research funding
94%
Of revenue goes to research and programs
23
Ongoing studies in 5 countries
Your gift can help improve, extend, and save lives.
A new phase III clinical trial called COMPETE (NCT03049189 ) compares everolimus, an oral targeted
Following the loss of a loved one, holiday traditions may be more painful than joyful.
Approximately 20% of all primary lung tumors are neuroendocrine (Hung 2019), including: Typical carcinoid (TC)
You can Spark Hope for a brighter future. Make a gift. Host an event. Or volunteer to help us advance our understanding of neuroendocrine tumors.
Learn about neuroendocrine tumor tests, treatments, and research. Find out about educational and inspirational events in the NET community.
NETRF hosts full-day free patient and caregiver neuroendocrine tumor conferences to educate and empower individuals to be part of their care planning and live their best life.
